Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The best treatment for resectable esophageal or gastroesophageal adenocarcinoma is unknown.
Although an operation to remove the esophagus is the most common treatment, previous studies
have shown that patients live longer when either perioperative (before and after surgery)
chemotherapy or preoperative (before surgery) chemotherapy plus radiation is given, compared
to surgery alone. However it is unknown which of these treatments (perioperative chemotherapy
or preoperative chemoradiation) is more effective in improving survival. A study where
patients with resectable esophageal / GE junction cancer are chosen at random to receive one
of the two preoperative treatments would help determine if one form of treatment improves
survival compared to the other.
Patients with localized esophageal / GE junction cancer (adenocarcinoma) will be randomized
to receive either preoperative and postoperative chemotherapy or preoperative chemoradiation
followed by surgery.
The main objective of this pilot trial is to determine the possibility of conducting a larger
study with many centers participating. If this study proves to be feasible with enough
patients enrolled and able to tolerate treatments without major side effects then we can
hopefully proceed to perform a larger multi-center trial to look for survival outcome
differences between patients who receive preoperative chemotherapy and those who receive
preoperative chemoradiation. The results of this trial would ultimately help us choose the
most effective treatment of resectable esophageal cancer and hopefully improve survival.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Dr. Gordon Buduhan
Collaborators:
CancerCare Manitoba London Health Sciences Centre Nova Scotia Health Authority University of Toronto